Tonix Pharmaceuticals Enters Securities Purchase Agreement with Point72 for 615,025 Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Tonix Pharmaceuticals entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase price of $16.259 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.001 per share exercise price of each pre-funded warrant. The closing of the offering is expected to take place on or about December 30, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering will be approximately $20M before deducting placement agent fees and other estimated offering expenses payable by the Company. TD Cowen is acting as sole placement agent for the offering. A.G.P./Alliance Global Partners is acting as a financial advisor.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like TNXP with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on TNXP
Wall Street analysts forecast TNXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNXP is 67.50 USD with a low forecast of 65.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.290
Low
65.00
Averages
67.50
High
70.00
Current: 18.290
Low
65.00
Averages
67.50
High
70.00
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tonix Pharmaceuticals to Present at January 2026 Investor Conferences
- Investor Conference Schedule: Tonix Pharmaceuticals will present at the Neuroscience Innovation Forum and Biotech Showcase on January 11 and 13, 2026, showcasing innovations in neuropsychiatric drug development, which is expected to attract potential investor interest.
- Leadership Participation: CEO Seth Lederman, M.D. will lead multiple sessions, emphasizing the company's leadership in biotechnology, aiming to enhance Tonix's market visibility and investor confidence.
- Product Line Showcase: Tonix will highlight its FDA-approved non-opioid analgesic TONMYA and other acute migraine treatments, demonstrating its market potential in chronic pain and CNS disorders.
- R&D Investment Outlook: Tonix's development pipeline includes candidates for rare diseases and infectious diseases, which is expected to generate interest in biotech investments and further enhance the company's competitiveness in the industry.
Continue Reading
Tonix Pharmaceuticals (TNXP) Enters $20M Securities Purchase Agreement with Point72
- Securities Purchase Agreement: Tonix Pharmaceuticals has entered into a securities purchase agreement with Point72 for the sale of 615,025 shares at $16.26 each, expected to close around December 30, subject to customary conditions, which will generate approximately $20 million in gross proceeds to enhance the company's liquidity for future R&D support.
- Pre-Funded Warrant Structure: In addition to common stock, the agreement includes pre-funded warrants allowing the purchase of 615,025 shares at $16.259 each, optimizing the financing structure and reducing overall financing costs for the company.
- Underwriter Role: TD Cowen is acting as the sole placement agent for this transaction, while A.G.P./Alliance Global Partners serves as financial advisor, ensuring smooth execution and boosting market confidence, reflecting investor trust in Tonix's future prospects.
- Funding Utilization Outlook: This financing will provide Tonix with essential capital to support ongoing investments in clinical trials and product development, particularly for the upcoming Phase 2/3 trial of TNX-4800, potentially driving long-term growth for the company.
Continue Reading